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Abstract 
This report describes a 21-year-old male patient who presented to a UK hospital with 
mild symptoms of fever, malaise and arthralgia. He had just returned from Hoga Islands 
(Indonesia) where he had spent six weeks. While examination was unremarkable, his 
blood showed a significant rise in liver function tests and a steady drop in white cells as 
well as platelets. Dengue serology was later found to be positive for anti-Dengue IgG as 
well as IgM. With supportive treatment, this young gentleman recovered quickly and was 
discharged with a plan for follow-up in the clinic. 
Case Report 
Mr. S.C., 21 years old, was admitted to a UK hospital feeling ‘increasingly unwell’ for 10 days. 
Among his presenting features were the following: fever, generalised joint ache, loss of appetite, malaise, 
dizziness and mild diarrhoea, including one episode of fresh rectal bleeding. He was otherwise well and 
denied other symptoms such as abdominal pain, nausea or vomiting, cough, photophobia or rashes. 
Prior to this Mr. S.C. had been fit and healthy with no past medical history. He was studying marine 
biology at University, was a non-smoker and drank only social alcohol. There was no significant family 
history. He had come back three days earlier from a six-week trip to Hoga Islands (Indonesia) where he 
had been doing biomarine research. Risk factors elicited were the following: (1) He had stopped taking 
his antimalarial tablets two weeks into the trip. (2) He had been drinking water from a well. (3) He had 
been diving in salt water. He denied any risk of sexually transmitted disease or intravenous drug use. 
On examination, Mr. S.C. was pyrexial with a temperature of 38.6°C. His pulse was 80 bpm and 
regular, blood pressure 131/72 mm Hg, respiratory rate 18/min and saturation on air 97%. His chest was 
clear, and normal heart sounds with no added murmurs could be heard on auscultation. His abdomen 
was soft and non-tender, and there was no evidence of any hepatosplenomegaly. Neurological 
examination was unremarkable and there was no peripheral oedema. 
Investigations 
Blood tests on admission were unremarkable apart from a raised CRP of 32 and a creatinine of 126. 
The following days eventually showed a particular trend in white cell count and platelet count, steadily 
dropping until August 31st, when Mr. S.C. was discharged (fig. 1, fig. 2). This was accompanied by a  
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contrasting rise in ALT over the same period of time (fig. 3). Investigations requested at that stage were 
as follows: chest X-ray: normal; thick and thin films (x3): all normal; stool MCS: normal; blood cultures: 
normal; hepatitis screen: negative; serology for typhoid, cytomegalovirus, and Epstein-Barr virus; 
serology for Dengue fever. 
Differential Diagnosis 
Malaria was first on the list of differentials to be excluded, given the combination of fever, diarrhoea 
and the fact that S.C. had stopped taking his antimalarial tablets two weeks into the trip. We were 
particularly worried about the possibility of Plasmodium falciparum, especially virulent, as it can cause 
end-organ damage to the central nervous system, kidneys and lungs. However, the absence of 
splenomegaly as well as the negative blood films made it less likely. Again top on the list of differentials 
was Dengue fever as it is endemic to Indonesia. Furthermore, the fever and arthralgia, accompanied by 
the raised LFTs and leucopenia, were all strongly suggestive of Dengue fever. However, there was no 
hepatomegaly or classical maculopapular rash often associated with the condition. In the UK, typhoid 
fever (also known as enteric fever), caused by the Gram-negative bacterium Salmonella typhi, is mostly 
seen in travellers returning from India. Typical features are a stepwise fever accompanied by relative 
bradycardia and a ‘rose spots’ rash on the torso. Swine flu needed to be excluded since Aylesbury has 
been a hotspot for the outbreak. Hepatitis was suspected as suggested by the deranged LTFs, fever and 
suspicious oral intake during the trip. 
Treatment 
Dengue was eventually confirmed by isolation of the virus in serum and detection of 
immunoglobulins (IgM as well as a five-fold increase in IgG titre) by enzyme-linked immunosorbent 
assay antibody capture. Treatment was mainly supportive, in the form of intravenous fluids and 
paracetamol. Transfusion was not required since the platelet count was above 20 × 10
9/l, the current 
threshold for transfusion.  
Outcome and Follow-Up 
As he started feeling better and his blood values were improving, Mr. S.C. was discharged after a 
week of hospitalisation. Second Dengue serology eventually came back again positive for IgG. Mr. S.C. 
came back a month later for an outpatient follow-up, and by that time his blood count as well as his 
biochemistry had normalised. 
Discussion 
Dengue fever is caused by one of the single-stranded RNA viruses of the Flavivirus 
genus. It represents the most common cause of arboviral disease (viruses transmitted by 
arthropods) and is endemic to the tropics. The incidence of Dengue fever is as high as  
50–100 million annually worldwide, and it is transmitted by the Aedes aegypti mosquito. 
There are four main Dengue virus serotypes; infection with one serotype produces 
lifelong immunity only to that serotype. Humans and mosquitoes are the principal hosts, 
and illness is only ever manifested in humans [1, 2]. Dengue fever has been on the rise 
lately due to several factors, namely: (1) population growth in the tropics; (2) poor 
management of waste and water in urban areas; (3) an increase in air travel, meaning 
humans import more viruses; (4) the fact that Dengue tends to be under-reported as it is 
not notifiable in most countries and often not diagnosed. Dengue fever has an incubation 
period of 3–14 days (normally 5–7). Humans with Dengue can pass it to other humans 
only via mosquitoes or blood products and only whilst febrile.   
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Clinical features can include any of the following: abrupt onset high fever (biphasic – 
the second fever occurs approximately 7 days after onset, after defervescence); severe 
headache; myalgia (breakbone fever); arthralgia; nausea, vomiting and diarrhoea; 
dizziness; loss of appetite; sore throat; cough; cutaneous hyperaesthesia; taste disturbance. 
Other features typically described involve: a rash in 50% of cases which is macular/ 
maculopapular with islands of sparing; flushed facies, effusions, ascites, and finally, 
hepatomegaly in up to 40% of patients. 
Laboratory features suggestive of Dengue fever are: leucopenia; neutropenia; 
lymphocytosis; raised LFTs; thrombocytopenia (platelet count <100 × 10
9/l); increased 
haematocrit; platelet count that tends to drop until temperature returns to normal [3]. 
The previous classification of Dengue as outlined by the World Health Organisation 
subdivided Dengue into 5 different categories, namely: (1) non-specific febrile illness; 
(2) classic Dengue; (3) Dengue haemorrhagic fever; (4) Dengue haemorrhagic fever with 
Dengue shock syndrome; (5) other unusual syndrome, e.g. encephalopathy [4–6]. It is 
very important to realise that this classification no longer holds true, as there have been 
several reports of difficulties in its use which were summarised in a systematic literature 
review [7, 8]. A new model for classifying Dengue has been recommended by a specialist 
group (Geneva, Switzerland, 2008) and has been tested in 18 countries. The new 
suggested dengue case classification and levels of severity are outlined below [9]. 
Criteria for probable Dengue include: live in/travel to a Dengue endemic area; fever 
and two of the following criteria: nausea, vomiting; rash; aches and pains; tourniquet test 
positive; leukopenia; any warning sign. Warning signs would include any of: abdominal 
pain or tenderness; persistent vomiting; clinical fluid accumulation; musocal bleed; 
lethargy or restlessness; liver enlargement >2 cm; increase in haematocrit concurrent with 
rapid decrease in platelet count. 
Criteria for severe Dengue include: severe plasma leakage leading to shock or fluid 
accumulation with respiratory distress; severe bleeding as evaluated by the clinician; 
severe organ involvement with: liver: AST or ALT > 1,000; CNS: reduced consciousness; 
heart and other organ involvement [10, 11]. 
Furthermore, depending on clinical presentation, patients are divided into 3 groups. 
Group A: These are patients who do not have any warning signs and may be sent home 
on oral fluids. Group B: These patients, who have warning signs, should be admitted to a 
secondary health care centre for close monitoring as they approach the critical phase. The 
immediate management includes obtaining a reference haematocrit prior to fluid therapy, 
initiating isotonic solution infusion, and re-assessing the haematocrit regularly. Group C: 
These individuals require emergency treatment as they present with severe Dengue as 
described earlier. As can be gathered from the above information, our patient would fit in 
category B, which is why he was admitted to hospital for intravenous rehydration as well 
as close monitoring. 
Learning Points/Take Home Messages 
(1) Dengue fever needs to be excluded in any returning traveller presenting with fever 
and malaise. (2) The diagnosis of Dengue fever would be suggested by leucopenia, 
thrombocytopenia and raised liver function tests. It is however confirmed by the presence  
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of IgG and IgM antibodies in serum. (3) Supportive management is the mainstay of 
treatment for complications such as Dengue haemorrhagic fever and Dengue shock 
syndrome. (4) The previous WHO classification of Dengue has been replaced by a clearer, 
much simplified version to help and guide management by healthcare professionals. 
(5) What is current knowledge: Dengue fever can deteriorate alarmingly fast with 
haemorrhagic manifestations, severe nausea and vomiting. (6) What is new here: Dengue 
fever can also follow a surprisingly mild course initially, but it is important to rapidly 
diagnose the illness so as to start the mainstay of supportive therapy efficiently, before the 
patient gets compromised. The article also describes the new WHO classification and its 
implication for treatment of patients presenting with features suggestive of Dengue. 
 
 
 
 
 
 
Fig. 1. White cells: trend with time. 
 
 
 
Fig. 2. Platelets: trend with time. 
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Fig. 3. ALT: trend with time. 
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